Quick Answer
Alaunos Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $1.39 million for the year ending 2025.
- Alaunos Therapeutics, Inc. showed an increase of +26.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Alaunos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2003 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2009: $7.08 million | Q3 2010: $66.47 million | Q1 2011: $124.04 million | Q3 2011: $118.93 million | Q1 2012: $128.01 million | Q2 2012: $110.39 million | Q3 2012: $95.33 million | Q1 2013: $55.66 million | Q2 2013: $38.93 million | Q3 2013: $23.63 million | Q1 2014: $60.39 million | Q2 2014: $53.00 million | Q3 2014: $46.12 million | Q1 2015: $129.68 million | Q2 2015: $118.55 million | Q3 2015: $163.84 million | Q1 2016: $124.85 million | Q2 2016: $109.00 million | Q3 2016: $94.68 million | Q1 2017: $66.45 million | Q2 2017: $97.19 million | Q3 2017: $84.41 million | Q1 2018: $51.11 million | Q2 2018: $40.40 million | Q3 2018: $31.73 million | Q1 2019: $51.49 million | Q2 2019: $43.56 million | Q3 2019: $88.42 million | Q1 2020: $171.00 million | Q2 2020: $153.52 million | Q3 2020: $135.47 million | Q1 2021: $100.06 million | Q2 2021: $76.75 million | Q3 2021: $91.73 million | Q1 2022: $68.26 million | Q2 2022: $60.01 million | Q3 2022: $37.81 million | Q1 2023: $23.50 million | Q2 2023: $18.32 million | Q3 2023: $11.94 million | Q1 2024: $4.15 million | Q2 2024: $2.46 million | Q3 2024: $1.68 million | Q1 2025: $319.0 thousand | Q2 2025: $2.88 million | Q3 2025: $1.94 million.
- Historical annual values: Fiscal year 2025: $1.39 million | Fiscal year 2024: $1.09 million | Fiscal year 2023: $6.06 million | Fiscal year 2022: $39.06 million | Fiscal year 2021: $76.05 million | Fiscal year 2020: $115.07 million | Fiscal year 2019: $79.74 million | Fiscal year 2018: $61.73 million | Fiscal year 2017: $70.95 million | Fiscal year 2016: $81.05 million | Fiscal year 2015: $140.72 million | Fiscal year 2014: $42.80 million | Fiscal year 2013: $68.20 million | Fiscal year 2012: $73.31 million | Fiscal year 2011: $104.71 million | Fiscal year 2010: $60.39 million | Fiscal year 2009: $48.84 million | Fiscal year 2008: $11.38 million | Fiscal year 2003: $0.00.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: